Key Takeaways
- An NEJM paper reports two phase 3 trials of retatrutide in adults with knee osteoarthritis and obesity: in TRIUMPH-4 (445 people, 68 weeks), WOMAC pain scores fell 3.96 points.
- Serious adverse events were more common on the drug (10.8% at 12 mg versus 2.0% on placebo in TRIUMPH-4), and one participant in each retatrutide group of that trial died.
- Retatrutide is investigational, approved nowhere, and the trials measured pain and function — not whether the drug slows joint damage.
A Weight Drug Walks Into an Arthritis Trial
Two phase 3 trials published in The New England Journal of Medicine asked a question nobody has answered with a drug before: can a powerful obesity medication treat knee osteoarthritis pain? The candidate is retatrutide, Eli Lilly's once-weekly triple agonist (GIP/GLP-1/glucagon), tested in people with painful knee OA and obesity — and without diabetes.
In TRIUMPH-4 — 445 participants, 68 weeks — the co-primary results were striking. On the WOMAC pain scale (0–10), scores fell 3.96 points at 9 mg versus 2.12 on placebo, and body weight fell 20.0% at 9 mg and 23.7% at 12 mg, versus 4.6% on placebo. A second population inside the TRIUMPH-1 obesity trial (574 participants, 80 weeks) pointed the same way: pain down 3.64 points at 12 mg versus 1.87 on placebo, weight down 24.8% versus 4.3%. Roughly two-thirds of treated participants in a pooled analysis achieved at least a 50% pain reduction, versus 37.8% on placebo.
The Bill, Itemized
The honesty beat matters more than usual here. Serious adverse events were more common on retatrutide than placebo in both trials — in TRIUMPH-4, 9.5% at 9 mg and 10.8% at 12 mg versus 2.0% on placebo — and one participant in each retatrutide group of TRIUMPH-4 died, with investigators assessing both deaths as unrelated to treatment. Discontinuation for adverse events reached 18.2% at the top dose. A peculiar side effect, dysesthesia (abnormal skin sensation), affected 20.9% at 12 mg in TRIUMPH-4 versus 0.7% on placebo.
Two boundaries, plainly: retatrutide is investigational — approved nowhere, for anything — and these trials measured pain and function in people not yet needing knee replacement. They say nothing about slowing the joint damage itself.
Health note: knee pain has many causes and established treatments; an investigational drug in a trial is not a treatment option — discuss persistent knee pain with your own clinician.
The Twikup Take
The science here is genuinely new — knees carrying less weight hurt less, and no pill has ever shown numbers like these for OA pain. But a trial where one in five top-dose participants quit and serious events ran five times the placebo rate is a beginning of a conversation, not an ending.
Image: Illustrative image.